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Abstract  
 
Metastatic pancreatic ductal adenocarcinomas (PDAC) are incurable due to the rapid 
development of resistance to all current therapeutics. Oncolytic adenoviral mutants 
have emerged as a promising new strategy that negates such resistance. In contrast to 
normal tissue, the majority of PDAC express the v6-integrin receptor. To exploit 
this feature, we modified our previously reported oncolytic adenovirus, Ad∆∆ to 
selectively target v6-integrins to facilitate systemic delivery. Structural 
modifications to Ad∆∆ include the expression of the small but potent v6-binding 
peptide, A20FMDV2 and ablation of binding to the native Coxsackie and Adenovirus 
Receptor (CAR) within the fibre knob region. The resultant mutant, Ad-3∆-A20T 
infected and killed v6-integrin expressing cells more effectively than the parental 
wild type (Ad5wt) virus and Ad∆∆. Viral uptake through v6-integrins rather than 
native viral receptors (CAR, v3- and v5-integrins) promoted viral propagation 
and spread. Superior efficacy of Ad-3∆-A20T compared to Ad5wt was demonstrated 
in 3D organotypic co-cultures, and similar potency between the two viruses was 
observed in Suit-2 in vivo models. Importantly, Ad-3∆-A20T infected pancreatic 
stellate cells at low levels, which may further facilitate viral spread and cancer cell 
elimination either as a single agent or in combination with the chemotherapy drug, 
gemcitabine. We demonstrate that Ad-3∆-A20T is highly selective for v6-integrin 
expressing pancreatic cancer cells and with further development, this new and 
exciting strategy can potentially be extended to improve the systemic delivery of 
adenoviruses to pancreatic cancer patients.  
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Introduction 
 
Pancreatic ductal adenocarcinomas (PDAC) are aggressive cancers with high 
mortality and low 5-year survival rates globally (1). Major reasons for the dismal 
prognosis are the late presentation of symptoms and the rapid development of 
resistance to all current therapeutics that do not significantly prolong survival (1, 2). 
Replication-selective oncolytic adenoviruses efficiently target all epithelial cancers 
including treatment-resistant pancreatic cancer cells and have excellent safety records 
in early phase clinical trials. The first oncolytic adenoviral mutant to be evaluated in 
pancreatic cancer patients was Onyx-015 (dl1520) with deletion of the E1B55K gene 
enabling virus-propagation in cancer cells with aberrant nuclear mRNA export and 
non-functional p53 (3-5). Despite proven safety in two Phase I trials in conjunction 
with gemcitabine, efficacy was limited because essential viral functions were 
compromised by the deletion. More recently, mutants with higher efficacy have been 
developed by deleting the small pRb-binding E1ACR2-region (∆CR2) that prevent 
replication in normal tissue while viral propagation and spread in tumour cells is 
complemented by deregulated cell cycle control (pRb-p16 regulation) (6-8). The most 
common genetic alterations in pancreatic cancer are activating KRAS mutations, 
CDKN2A/p16 deletion, and inactivating TP53 mutations (9) and consequently, 
replication of E1A∆CR2 mutants readily proceeds. E1A∆CR2 mutants have not yet 
been evaluated in PDAC patients while promising outcomes were reported in gliomas 
and osteosarcomas with Ad5∆CR2-variants (8, 10).  
We recently developed the novel mutant Ad∆∆ with the anti-apoptotic E1B19K gene 
deleted in addition to the E1ACR2-deletion (6, 11, 12). E1B19K is a functional Bcl-2 
homologue that binds Bax and Bak, and inhibits mitochondrial pore formation and 
apoptosis in response to death receptor-activation and intrinsically induced apoptosis 
(13). Ad∆∆ synergized with the current clinical standard of care for pancreatic cancer, 
gemcitabine and irinotecan, without toxicity to normal cells (6, 11, 14). However, to 
efficiently target pancreatic cancer lesions in patients by systemic administration 
required further modifications. Human erythrocytes express high levels of the native 
viral receptor, Coxsackie and Adenovirus Receptor (CAR) and Complement Receptor 
1 (CR-1) that bind the viral fibre knob in the presence of neutralizing antibodies and 
complement, resulting in lower doses of virus reaching the tumour (15). Other 
barriers to systemic delivery are the rapid elimination of virus by hepatic Kupffer 
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cells and hepatocyte uptake, and the high affinity binding to numerous blood factors 
(16-18). For example, Factor X (FX) binds to the viral hexon protein and bridges the 
virus to heparan sulfate proteoglycans (HSPGs) mainly on the hepatocyte surface and 
promotes liver transduction (17). Factor IX (FIX) has also been reported to aid the 
transduction of hepatocytes although, it remains unclear which viral protein is 
responsible, and complement-4 binding protein (C4BP) binds to the fibre knob (16, 
18). Importantly, viral binding to blood factors rapidly induces innate immune 
activation to the vector resulting in systemic inflammatory responses in patients (18, 
19). We hypothesised that the local viral concentration at tumour sites could be 
increased by, i) targeting of mutants to pancreatic tumours and, ii) decreasing binding 
to erythrocytes and blood factors. Ultimately, we generated a novel oncolytic 
adenovirus modified to improve tumour targeting.    
The vß6-integrin is highly expressed in many solid tumours but not in normal cells 
(20-22). To take advantage of the selective expression of vß6-integrin in PDAC 
cells, we previously generated the retargeted wild type mutants Ad5A20 and 
Ad5A20-477dlTAYT (23, 24). The mutants were engineered to express a 20 amino 
acid peptide A20FMDV2 derived from the foot-and-mouth disease virus (FMDV) 
that selectively binds through an Arg-Gly-Asp (RGD)-domain to vß6 (25, 26). Ad5-
A20477dlTAYT was also modified to reduce CAR and complement binding and 
partially relieved some of the obstacles with systemic delivery by reducing 
erythrocyte binding (23, 24). 
In this study we report on the generation of a novel mutant, Ad5-3∆-A20T based on 
the oncolytic mutant Ad∆∆, with incorporation of the A20FMDV2 peptide, ablation 
of CAR binding and deletion of E3gp19K, for optimal replication-selectivity, cancer 
targeting and immune stimulation. Ad5-3∆-A20T potently replicated in and killed 
cultured PDAC cells, in xenografts in vivo and in 3-dimensional co-culture models 
with pancreatic stellate cells. Ad5-3∆-A20T was highly efficacious and retained all 
viral functions necessary for propagation in pancreatic cancer cells also in the 
presence of gemcitabine. We expect these findings to guide further optimisation of 
oncolytic adenoviruses for systemic delivery to improve on therapeutic efficacy in 
patients with pancreatic cancer in conjunction with current treatments.  
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Materials and Methods  
 
Cell lines and culture conditions  
Human pancreatic ductal adenocarcinoma (PDAC) cell lines were used in the study: 
BxPC-3, Panc04.03, Capan-2, PANC-1, and MiaPaCa-2 (primary tumours); CFPAC-
1 and Capan-1 (liver metastasis), Hs766t (lymph node metastasis) (ATCC, LGC 
Standards, UK), and Suit-2, PaTu8902 and PaTu8988t (liver metastasis) and 
PaTu8988s (primary tumour) (Cell Services, Cancer Research UK). The PT45 cells 
(primary tumour) were a kind gift from Prof H. Kalthoff (Comprehensive Cancer, 
Campus Kiel, Germany). The hTERT-immortalised human pancreatic stellate cells 
(PS1) were a kind gift from Prof. H. Kocher (BCI, QMUL, London) (27). The human 
embryonic kidney cells HEK293 and JH293 (Cell Services, Cancer Research UK) and 
the human lung carcinoma cells A549 (LGC Standards, UK) were used for viral 
production. Cells were grown at 37°C and 5% CO2 in Dulbecco Modified Eagle's 
medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% 
penicillin and streptomycin (Penicillin 10000 units/ml, Streptomycin 10mg/ml; P/S) 
(Sigma-Aldrich, MO). All cell lines were STR-profiled (LGC Standards, UK and 
Cancer Research UK) and verified to be identical to the profiles reported by the 
suppliers and to the original vial.  
 
Organotypic 3-dimensional (3D) co-culture models 
The development of the 3-dimensional co-culture models (organotypic cultures) for 
pancreatic adenocarcinoma cells and stromal cells has been previously described in 
detail elsewhere (27-29). Briefly, collagen type I was mixed with Matrigel at different 
ratios, typically 3:1, in Transwells® (Corning; Sigma-Aldrich) and placed in 24-well 
plates. Panc0403 or Suit-2 cells were seeded together with PS1 cells (typical ratio 1:2; 
total 1x10
5
cells/well) on top of gels in 10% FBS Ham’s F12/DMEM (GIBCO). After 
24h the media in the top-chamber was replaced with serum-free DMEM, 3-4 days 
later viruses were added at 2-5-fold higher doses than in regular 2D-cultures and fixed 
in formalin 4-7days later.  In some studies cells were embedded within the gels and 
virus added either in the top or bottom compartment. In combination studies 
gemcitabine (Gemzar; Eli Lilly, IN) was added at 5-10nM in serum-free DMEM on 
top of gel and/or in 10% FBS Ham’s F12/DMEM underneath the transwell.  
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Viruses and infections  
Wild-type virus Ad5 and the modified EGFP-expressing mutants, Ad5, Ad5A20 and 
Ad5A20-477dlTAYT were previously generated from species C wild-type adenovirus 
type 5 (23, 24). Briefly a 20-amino acid RGD-binding peptide (A20FMDV2; 
NAVPNLRGDLQVLAQKVART (26)) from VP1 of the foot-and-mouth disease virus 
(FMDV) (30) was incorporated in the HI-loop of the Ad5 fibre knob in Ad5A20 (23). 
Ad5A20 was further modified to generate Ad5A20-477dlTAYT through a base 
substitution Y477A and a deletion of amino acids 489-492 (TAYT) in the fibre knob 
and the E3gp19K gene was replaced by EGFP (18, 24, 31). Generation of Ad∆∆ 
(deleted in E1ACR2 and E1B19K) has previously been described (6, 12). Ad5-3∆-
A20477dlTAYT (Ad5-3∆-A20T) was generated by two-step homologous 
recombination in SW102 bacteria (32, 33). The wild-type Ad5 genome previously 
captured within a bacterial artificial chromosome (BAC) was modified in a series of 
stages (primer sequences; Supplementary Table 1). First, the wild type E1 genes were 
replaced with the PCR amplified modified E1-region from Ad∆∆. Next, the fibre 
knob domain of Ad5A20-477dlTAYT was PCR amplified and inserted to replace the 
wild-type knob. Finally, the E3gp19K domain was deleted generating Ad5-3∆-A20T. 
The viruses were produced, purified and characterised according to standard protocols 
(6, 12). The viral particle (vp) to infectious unit (plaque-forming units; pfu) was 9-
45vp/pfu for all viruses with the highest ratios for the FMDV expressing mutants. All 
infections were performed in serum-free DMEM and 2h later the media was replaced 
with 10% FBS/1% P/S DMEM ± the indicated doses of drugs. 
 
Cell viability assay 
Cells were infected with viral mutants in 2% FBS/1% P/S DMEM and were assayed 
72h or 96h later using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium assay (MTS; Promega, Southampton, UK) to 
quantify live cells as an indirect measurement of cell death. Dose–response curves 
were generated to determine the concentration of each virus killing 50% of cells 
(EC50) using untreated cells as controls. Each data point was generated from triplicate 
samples and experiments repeated at least three times as described previously (12). 
 
Viral genome amplification by qPCR 
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Cells were infected with 100 particles per cell (ppc) of the respective virus and were 
harvested 4, 24, 48 and 72h later. The cell suspensions were pelleted, snap-frozen and 
stored at -80ºC. DNA was extracted using the QIAamp DNA Blood Mini Kit, 
according to the manufacturer’s instructions (Qiagen, Netherlands) and used for 
quantitative PCR (qPCR) analysis as previously described (11, 14).  
 
Viral replication assay by tissue culture infectious dose (TCID50)  
Cells were infected as described for qPCR and cells and media were collected at the 
indicated time points, freeze-thawed, and analyzed by the TCID50 limiting dilution 
method on JH293 or A549 cells. Ad5 wild type virus of known activity was included 
in every assay as internal control as previously described (14). 
 
Quantification of infectivity and cell surface receptor levels 
Cells were seeded (1x10
5
cells/well) in 6-well plates 24h prior to infection with the 
EGFP-expressing mutants at 100 or 500ppc in serum free DMEM, 2h later media was 
replaced with 10% FBS/DMEM. Viral infectivity was quantified by flow cytometry 
analysis (FACs) using EGFP expression as a marker, 48h and 72h post-infection. 
Cells were detached with trypsin/EDTA and combined with non-attached cells in the 
media and re-suspended in cold FACS buffer (0.1% BSA/DMEM).  
To quantify cell-surface receptors cells were grown and treated as described above, 
re-suspended and incubated on ice for 1h with the respective primary mouse 
monoclonal antibody; anti-Coxsackie and Adenovirus Receptor (anti-CAR at 1:1000; 
ATCC), anti-v3-integrin (1:100; Chemicon), anti-v5 (1:100; Cancer Research 
UK) and anti-v6 (1:100; Clone 10D5, Millipore). Bound antibodies were detected 
with secondary goat anti-mouse IgG conjugated to fluorescein isothiocyanate (FITC; 
Alexaflour 488 at 1:250; Molecular Probes) for 1h. To determine the role of each 
receptor, antibodies targeting v5 or v6 (at 1:100) or the A20FMDV2 peptide 
(10nM) were incubated with the cells for 10min on ice prior to the addition of virus. 
EGFP expression and cell surface protein levels were determined by detection of 
fluorescence on the FACSCalibur instrument acquiring 10,000 events per sample and 
analyzed using the FlowJo software 8.8.6 (Tree Star Inc.).  
 
Immunohistochemistry (IHC) 
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Formalin fixed paraffin embedded cells, organotypic cultures or tissue sections 
(10µm) were dewaxed, rehydrated in decreasing ethanol concentrations, water and 
PBS. Antigen retrieval was performed by boiling in 10mM Sodium Citrate Buffer 
pH6 for 8min, followed by water and PBS at 24°C.  Cell permeabilisation was for 5 
min in 0.2% Triton-X/PBS in blocking buffer (2% BSA/10% FBS/PBS). Primary 
antibodies, SMA (1:300; M0851, Dako) and E1A (1:500; M58, GeneTex) were 
incubated overnight at 4
o
C, followed by fluorescent-labeled secondary anti-mouse 
antibodies for 1h (1:500; Alexa Fluor 488, ThermoFisher). Sections were stained with 
4’,6’-diamidino-2-phenylindole (DAPI, 1mg/ml; ThermoFisher), mounted with 
FluorSave Reagent (Calbiochem), stored at -20
o
C and analysed by confocal 
microscopy (Zeiss 710). 
Tumours were harvested at the end of the study and fixed in 4% formaldehyde. The 
fixed tissues were sectioned and processed for histopathology with hematoxylin and 
eosin (H/E) and for IHC by staining for E1A and hexon (1:2000; AutogenBioclear) 
followed by detection using HRP-conjugated secondary antibodies (Dako).  
 
In vivo tumor growth 
Tumor cells were inoculated subcutaneously in one flank of CDnu/nu athymic mice 
(Charles River, UK) with Suit-2 cells in sterile PBS (1x10
6
cells/200µl). Treatments 
were initiated when tumor volumes reached 100±20μl (14 days after inoculation) by 
intratumoural administration of adenoviral mutants at doses ranging from 1x10
8 
- 
3x10
9
vp/injection, on day 1, 3 and 6 or day 1, 3, 5, 7 and 9. Tumor growth, 
progression and animal weight were followed until tumors reached 1.44cm
2
 or until 
symptomatic tumor ulceration occurred (according to UK Home Office Regulations). 
Tumor volumes were estimated twice weekly: volume = (length x width
2
 x π)/6 and 
growth curves were compared using one-way Anova. Survival analysis was 
performed according to the method of Kaplan-Meier (log rank test for statistical 
significance). Each treatment group included 8 animals and studies were performed 
twice according to two protocols as described above. For viral distribution studies, 
virus was administered via the tail vein with a single injection of 3x10
9
vp in 100µl. 
Tumours were harvested 24, 48 and 72h later, sonicated, and protein expression 
determined by Western blotting (Supplementary Materials and Methods). E1A was 
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detected by mouse anti-E1A (1:500; M58, GeneTex) and PCNA by mouse anti-
PCNA (1:1000; Santa Cruz Biotech). 
 
 
Results 
 
Pancreatic cancer cells express higher levels of vß6-integrin than Coxsackie 
Adenovirus Receptor (CAR) and are more susceptible to infection with A20FMDV2-
retargeted mutants than with Adwt.  
Pancreatic tumours frequently express the vß6-integrin, reported to play a role in the 
progression of pancreatic cancer (21, 34). A panel of 15 human pancreatic cancer cell 
lines was screened for vß6-integrin expression to determine the feasibility of 
retargeting the replication-selective Ad∆∆ to this integrin. Expression levels were 
high in the majority of cell lines while levels of the native adenovirus receptor CAR, 
were consistently low compared to the JH293 cells (Fig. 1A and Supplementary Fig. 
1A). The degree of infectivity with the FMDV2-expressing Ad5A20 (targeting vß6 
and CAR) and Ad5A20-477dlTAYT (targeting vß6 only) was markedly higher than 
with wild type Ad5 (Ad5wt; targeting CAR only) across all cell lines that expressed 
the vß6-integrin (Fig. 1A-B and Supplementary Fig. 1B). Infection levels strongly 
correlated with vß6-integrin expression (R2=0.7; Fig. 1C). In contrast, no correlation 
was obtained between Ad5A20- or Ad5A20-477dlTAYT-infection and CAR-levels or 
between Ad5wt-infection and vß6-integrin expression levels (R2≤0.2; 
Supplementary Fig. 1C-D).  
After the initial screening of 15 cell lines, we selected 5 of these for further in depth 
studies that represented a range of vß6-integrin expression levels; PT45 low, 
Panc04.03 high, and MiaPaca-2, Suit-2, and BxPC-3 intermediate (Fig. 1A). Infection 
in Suit-2 and Panc04.03 cells were significantly higher with Ad5A20 and Ad5A20-
477dlTAYT compared to infection with Ad5wt (p<0.05; Suit-2 and p<0.01; 
Panc04.03) (Fig. 2A).  A similar trend was observed in BxPC-3 cells while in 
MiaPaCa-2 or PT45 cells all viruses infected to a similar degree. Infection levels in all 
five cell lines strongly correlated with the expression levels of vß6-integrin 
(Ad5A20, R
2
=0.99; Fig. 2B). The A20FMDV2-expressing mutants caused 
significantly higher levels of cell killing in Suit-2 and Panc04.03 cells compared to 
Ad5wt (p≤0.05) but not in PT45, MIA PaCa-2a or BxPC-3 (Fig. 2C). The BxPC-3 
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cells were the most sensitive to Adwt infection with the lowest EC50-values of all 
tested cell lines (Supplementary Table 2). Despite higher levels of infection with the 
retargeted Ad5A20TAYT and Ad5A20 mutants in BxPC-3 cells (Fig. 2A) it is 
possible that the lower EC50-values for both Adwt and mutants masked small 
differences in cell killing ability in these cells.   
 
Viral genome amplification is increased with A20FMDV2-expressing mutants in cells 
expressing high levels of the vß6-integrin.  
In Suit-2 and Panc04.03 cells, the enhanced infection and cell killing with the 
A20FMDV2-mutants were paralleled by higher levels of viral genome amplification 
compared to infection with Ad5wt at all time points (24-72h) (Fig. 2D). In agreement 
with the cell killing and infectivity data, Ad5wt genome amplification was greater in 
PT45 cells with a similar trend in MiaPaCa-2 cell. In BxPC-3 cells, all three viruses 
replicated to similar levels. In conclusion, variations in the absolute levels of genome 
amplification between Ad5wt and the retargeted mutants directly reflected the 
different levels of viral uptake (24h time point) for each cell line as a consequence of 
the increased number of viral genomes available after infection. In contrast, the 
relative replication rates of the retargeted mutants in individual cell lines remained 
similar to Ad5wt.   
 
Blocking vß6-integrin attenuates infection with Ad5A20 and Ad5A20-477dlTAYT but 
not with Ad5wt. 
The vß3- and vß5-integrins play a major role in internalisation of Ad5wt, mediated 
by penton-integrin binding through RGD-interactions. To examine whether these 
integrins were also essential for the FMDV-retargeted mutants or whether binding to 
the vß6-integrin alone was sufficient for cellular uptake of virus, we first determined 
the expression levels of vß3- and vß5-integrins (Fig 3A). PT45 and Suit2 cells 
expressed the highest levels of vß5-integrins and BxPC-3 of the vß3-integrin. The 
greatest expression of vß6-integrins was observed in Suit-2 and Panc04.03 cells. 
Blocking of vß6-integrin receptors with free A20FMDV2 peptide significantly 
decreased the infection levels with Ad5A20 and Ad5A20-477dlTAYT but not with 
Ad5wt in Panc04.03, Suit-2 and BxPC-3 cells (Fig. 3B). The most pronounced effect 
was in Suit-2 and Panc04.03 cells with reductions up to 70% compared to original 
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levels of infection. Decreased E1A-expression in cells infected with Ad5A20-
477dlTAYT but not with Ad5wt further confirmed our findings (Panc0403; 
Supplementary Fig. 1E). Thus, Ad5A20 and Ad5A20-477dlTAYT were mainly 
internalised through vß6-integrins in pancreatic cancer cells although, other 
integrins such as vß5 may contribute towards the process. Importantly, in cells with 
low or non-detectable levels of vß6-integrins, infection with the retargeted mutants 
was reduced compared to infection with Ad5wt (Fig. 3A-B and Fig. 1B). 
 
Viral replication and spread is supported in organotypic 3-dimensional (3D) co-
cultures of pancreatic cancer and stromal cells.  
Pancreatic cancer cells (PDAC) in situ are typically embedded in a dense tumour-
supporting fibrous stroma, with pancreatic stellate cells as a major component 
promoting invasion and restricting delivery of drugs to the tumour (35, 36). To 
explore efficacy of the Ad5A20 and Ad5A20-477dlTAYT mutants under conditions 
that are more similar to the tumour micro-environment than 2-dimensional 
monocultures, Panc04.03 or Suit-2 cells were co-cultured with transformed non-
tumorigenic pancreatic stellate cells (PS1) in 3-dimensional (3D) collagen-matrigels 
(27-29). Growth of both cancer cell lines were greatly increased in the presence of 
PS1 cells, forming duct-like structures when seeded and cultured within the gels 
(Supplementary Fig. 2), as previously reported for organoids established from human 
and murine pancreatic tumour tissue (37-39). Panc04.03 or Suit-2 cells seeded 
together with PS1 cells on top of gel matrices formed thick epithelial layers with 
increased cellular invasion into the substrate (Fig. 4Aii; top panels). However, in the 
absence of PS1 cells, the cancer cells mostly formed monolayers on top of the gels 
and did not invade the matrices (Fig. 4Ai). The 3D-culture conditions were 
compatible with adenoviral propagation regardless of where the cells were seeded 
(Fig. 4A and Supplementary Fig. 2). After 4 days of co-culturing PS1 cells with 
Panc04.03 or Suit-2 cells, the addition of Ad5wt and Ad5A20 resulted in viral spread 
through multiple cell layers when cells were seeded on top of the gels. The thickness 
of the uppermost epithelial layers decreased with increased viral dose, demonstrating 
virus-dependent cell killing (Fig. 4A; middle and bottom panels). The cell killing was 
greatest with the Ad5A20 mutant in Panc04.03 cells with few remaining live E1A-
positive cells 4 days after infection (Fig. 4A; confocal images). The effect was similar 
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in Suit-2 cells although, the inhibition of invasion and growth was less than in 
Panc04.03 cells (Fig. 4A; right panels). Importantly, we demonstrate that the infected 
epithelial cells were in sufficiently close contact with the PS1 stromal cells for virus 
to spread through the matrix and infect both cancer and stromal cells (Fig. 4B).  
Viral infection and replication in PS1 cells were initially determined in 2-dimensional 
monocultures (Fig. 4C). As expected for non-epithelial cells the level of infection was 
poor with the highest levels for Ad5wt with <10% of cells expressing EGFP, and 
<5% for the retargeted mutants compared to 20-50% in vß6-integrin-expressing 
epithelial cancer cells (Fig. 4C and 3B). Importantly, the early viral E1A gene was 
expressed at detectable levels in the PS1 monolayers (Supplementary Figure 3A-B). 
Viral uptake was likely mediated by vß3- and vß5-integrins (Fig. 4D), and was 
significantly reduced in the presence of an anti-vß5-integrin antibody (Fig 4C). CAR 
and the vß6-integrin were not detected in PS1 cells (Fig. 4D). We tested whether 
viruses could be released from infected PS1 cells and spread to neighbouring cancer 
cells. After infecting PS1 cells with Adwt or Ad5A20, following a 72h incubation 
period, the cell-free culture media was transferred to Panc04.03 and Suit-2 
monocultures. Potent viral infection and early gene expression was observed in both 
cancer cell lines (shown for Panc04.03; Fig. 4E). Viral spread was also confirmed in 
3D cultures by a similar two-step process; PS1 cells pre-seeded onto matrices were 
infected with viruses and after removal of excess free virus (48h post infection), non-
infected Panc04.03 or Suit-2 cells were seeded on top. Sufficient virions were 
produced from the PS1 cells to infect and eliminate the majority of the cancer cells 
72h post-infection (Fig. 4F). These findings collectively provide evidence that the 
retargeted adenoviral mutants infected both pancreatic stellate and cancer cells and 
could spread from cell-to-cell in the 3D culture system that represents the tumour 
microenvironment more accurately. 
 
The novel retargeted and replication-selective oncolytic mutant Ad5-3∆-A20T is 
highly efficacious in pancreatic cancer cell lines. 
To further exploit the selective targeting to vß6-integrins on pancreatic cancer cells, 
the A20FMDV2 peptide was inserted and CAR-binding was ablated in the fibre knob 
(HI-loop) of the Ad∆∆ mutant, to generate Ad5-3∆-A20T (Fig. 5A and 
Supplementary Fig. 1B) (6, 23, 24). In addition to the E1ACR2 and E1B19K 
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deletions in Ad∆∆ that provide replication-selectivity and apoptosis-enhancement, 
deletion of the TAYT-motif and the point-mutation at Y477A were included to reduce 
CAR-binding. These mutations and the insertion of the A20FMDV2 peptide were 
identical to the alterations in the parental Ad5A20-477dlTAYT mutant (18, 24, 40) 
(Fig. 5A and Supplementary Fig. 1B). The resulting oncolytic mutant Ad5-3∆-A20T 
killed Panc04.03 and Suit-2 cells more potently than the parental Ad∆∆ mutant 
demonstrated by 10- and 5-fold lower EC50-values (Fig. 5B; left panel). In contrast, in 
PS1 cells that were significantly less sensitive to virus-induced cell killing (>10-fold 
higher EC50-values), the novel mutant had similar cell killing potency as Ad5wt (Fig. 
5B; right panel). Replication of Ad5-3∆-A20T in Panc04.03 and Suit-2 cells was 
slightly less than for Ad∆∆ (Fig. 5C). Replication in PS1 cells was also less for Ad5-
3∆-A20T than for Ad∆∆. However, both viruses showed >100-fold lower levels of 
replication in PS1 than in epithelial cells; Ad5-3∆-A20T replication was 4.2x105± 
2.2x10
5
 pfu/ml and Ad∆∆ 1.7x107± 5.1x106 pfu/ml (n=3) 48h post-infection in the 
stromal cells. 
 
Ad5-3∆-A20T potently inhibits growth and invasion of Panc0403 cells in 3D co-
cultures with the pancreatic stromal PS1 cells.  
Dose-dependent cell killing was observed when 3D co-cultures of Panc04.03-PS1 
cells were infected with Ad5-3∆-A20T or Ad∆∆ (500 and 1000ppc) for 4 days 
(Panc04.03; Fig. 5D). In cultures infected with Ad5-3∆-A20T, viable and/or invading 
cells appeared to be fewer than in Ad∆∆-infected cultures at the lower dose, while the 
higher dose eliminated most cells with both viruses. Importantly, the efficacy of Ad5-
3∆-A20T was retained in organotypic co-cultures of Panc04.03 or Suit-2 with PS1 
cells when treated simultaneously with gemcitabine (Suit-2; Fig. 5E and 
Supplementary Fig. 4).  We previously demonstrated that both Ad∆∆ and Ad∆19K 
synergised with low doses of gemcitabine in pancreatic cancer cells in 2D 
monocultures and in vivo, including Suit-2 models, by enhancing apoptotic death 
through mitotic aberrations (11, 14). We found that the 3D co-culture system was a 
suitable model for screening the efficacy of adenoviral mutants and for confirming 
compatibility with current therapeutic cytotoxic drugs.  
 
Ad5-3∆-A20T efficiently inhibits growth of human pancreatic cancer xenografts in 
murine models.   
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The potent elimination of Panc04.03 and Suit-2 cells grown in 2D mono- and 3D co-
cultures were confirmed in vivo, using Suit-2 xenografts grown subcutaneously in 
athymic mice. We have previously demonstrated that the Suit-2 model is suitable for 
determining efficacy of adenoviral mutants administered alone or in combination with 
cytotoxic drugs (12, 41). Both Adwt and Ad5-3∆-A20T potently prevented tumor 
growth up to 20 days after the first administration of virus (Fig. 6A). From 20-42d 
growth was greatly reduced compared to the mock-treated animals that were culled 
already after 18 days due to tumour burden and ulcer formation. The median time to 
tumor progression was significantly prolonged (p<0.0004) from 11d for mock-treated 
animals to 42d with Ad5-3∆-A20T and 37d for Adwt (Fig. 6B). Tumours harvested 
when animals were culled showed intense E1A expression for both viruses up to 53d 
after virus-administration (Fig. 6C). The ultimate goal of generating Ad5-3∆-A20T 
was to increase viral dose at tumour lesions after systemic delivery. In this proof-of-
concept study, potent expression of E1A was observed in Suit-2 tumours after a single 
tail vein administration of Ad5-3∆-A20T (Fig. 6D). Interestingly, E1A expression 
appeared to be lower after tail vein injection with Adwt. The results from the 3D co-
cultures and the in vivo studies demonstrated that Ad5-3∆-A20T was at least as 
efficacious as Ad5wt under conditions that more realistically mimic the tumour 
microenvironment in situ in patients. Future studies will be aimed at quantifying the 
retargeting efficacy in murine models that can mimic the conditions in patients more 
accurately including systems with humanised blood factors. Taken together our data 
support further exploration of Ad5-3∆-A20T for potential future development into 
novel anti-cancer agents targeting pancreatic cancer. 
 
Discussion  
 
No curative treatments are currently available for patients with metastatic PDAC, and 
resistance to chemotherapeutics inevitably develops. The recent identification of 
several biomarkers will hopefully enable earlier detection and curative surgery in 
more patients (42, 43). In contrast, replication-selective oncolytic adenoviral mutants 
target pancreatic cancer at any stage by direct oncolysis, reversal of drug resistance 
and activation of anti-tumour immune responses but have poor efficacy when 
delivered systemically (8, 10). The focus of our study was to optimize the potent and 
selective oncolytic mutant Ad∆∆ (6) to enable future development of this mutant for 
systemic delivery by taking advantage of the selective expression of vß6-integrin in 
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pancreatic cancer cells. We generated the replication-selective integrin-targeted Ad5-
3∆-A20T mutant expressing the small vß6-peptide ligand A20FMDV2. The 
A20FMDV2 peptide was derived from the GH-loop in VP1 in the capsid of the foot-
and-mouth disease virus (FMDV) and is essential for infection in cloven-hoofed 
animals (44). The affinity to vß6-integrins was high, measured at KD=0.22nM, while 
binding to other integrins, including vß3, vß5 and vß1 was more than 80-fold 
lower (21, 25). The selective binding to vß6-integrins was shown to be dependent on 
the DLXXL motif in the carboxy -helical loop next to the RGD-domain at the apex 
of the loop domain in the peptide (23, 26, 44, 45). 
We previously demonstrated that the retargeted wild type mutants Ad5A20 and 
Ad5A20-477dlTAYT infected breast and ovarian carcinoma cells expressing the 
vß6-integrin (23, 24). In the current study, we demonstrated that infection with these 
mutants strongly correlated with vß6-integrin levels in a panel of fifteen PDAC cell 
lines. In two cell lines that express relatively high levels of vß6-integrins (CFPAC-1 
and Capan-2), lower than expected levels of infection with the retargeted mutants 
were observed. In the same cell lines, lower infection levels were demonstrated with 
Ad5wt which overall suggest that these cells are generally insensitive to viral 
infection and/or viral gene expression. Correspondingly, transduction of CFPAC-1 
cells with native Ad5, expressing a reporter gene, was demonstrated to be less 
efficient than of MIA PaCa-2, PANC-1 and BxPC-3 cells (46). Infectivity was 
monitored by viral EGFP expression, which in turn was regulated by the early viral 
E1A gene product, suggesting that both retargeted mutants entered the early 
endosomes even when attachment was through the vß6-integrin rather than CAR. 
The classical route of internalization of native Ad5 is via fibre knob-binding to CAR 
on epithelial cells, which initiates binding of penton base proteins to vß3- and vß5-
integrins through RGD-motifs, activating clathrin-mediated endocytosis (47). 
Acidification of the virus-containing endosome is required for release of viral 
genomes and proteins into the cytosol and for transport into the nucleus and 
completion of the viral life cycle. The level of infection by the retargeted mutants 
correlated with expression levels of the vß6-integrins and was reflected in the degree 
of cell killing in all the selected cell lines except BxPC-3. This cell line expressed all 
the tested integrins (vß3-, vß5-, and vß6) and CAR. The presence of these 
receptors likely contributed to the high sensitivity to Adwt infection producing the 
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lowest EC50-values of all tested cell lines allowing for only small differences in cell 
killing ability between Adwt and the retargeted mutants. It is interesting to note that 
both Panc04.03 and Suit-2 have low levels of CAR and the vß3-integrin and the 
highest levels of vß6-integrin expression, the reverse of the BxPC-3 cells.  
To further support the notion that our retargeted mutants likely internalise and infect 
in a similar way to wild type virus, we showed that total viral genome amplification 
paralleled the levels of infectivity, whereas the rate of replication remained similar to 
that of Ad5wt in each cell line. Thus, viral propagation was not hampered by the 
retargeted fibers and nuclear entry of the viral genome could proceed. Internalisation 
of the re-targeted mutants via vß6-integrin was confirmed by blocking infection 
with free A20FMDV2 peptide. Intracellular processing of the FMDV virus is less 
established, but includes a pathway similar to that of Ad5, with additional 
intracellular mechanisms implicated (48). It was recently reported that binding of the 
A20FMDV2 peptide alone to normal human bronchial epithelial (NHBE) cells caused 
rapid internalization of the peptide-vß6-integrin complex in endosomes although, 
the post-internalisation events were suggested to be more complex with partial delay 
of recycling of the integrin to the cell surface (25). Nevertheless, our vß6-integrin 
retargeted Ad5 mutants infected and replicated to similar levels as Adwt in PDAC 
cells. The exact cellular factors involved in the internalization, endocytosis, nuclear 
transport or the rate of cellular processing, may differ for viruses internalized via 
vß6- compared to vß3- and vß5-integrins. Interestingly, pancreatic stellate cells 
that lack vß6-integrins were infected by Ad5-3∆-A20T, suggesting that uptake in 
these cells was dependent on other integrins including vß5, in the presence of high 
local doses of virus. These processes are the subjects for future investigations.  
Following the initial proof-of concept studies, the chimeric fiber from Ad5A20-
477dlTAYT was engineered into the Ad∆∆ mutant to generate Ad5-3∆-A20T. The 
additional modifications to the CAR-binding region of the fibre-knob were also 
retained as a strategy to facilitate systemic delivery in future studies. We previously 
found that Ad5A20-477dlTAYT had improved liver-to-tumour viral genome ratios 
possibly through abrogation of FIX/C4BP-binding due to the TAYT-deletion (18, 24). 
Importantly, Ad5A20-477dlTAYT did not agglutinate erythrocytes due to de-
targeting of CAR through the Y477A mutation. The novel Ad5-3∆-A20T mutant 
infected and killed vß6-integrin expressing PDAC cells more efficiently than both 
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Ad5wt and the parental Ad∆∆ mutant. Viral functions including infection, gene 
expression and viral replication were retained, supporting propagation in all tested 
cell lines. However, replication was slightly lower with the new mutant than with 
Ad∆∆, indicating that the increased viral uptake and consequently, early viral gene 
expression, initiated cell killing before maximal number of virions were produced, as 
previously demonstrated in NHBE cells and PDAC cells treated with viral replication-
inhibitors (12). Furthermore, Ad5-3∆-A20T had approximately a 4-fold higher vp/pfu 
ratio compared to Adwt or Ad∆∆ although, production in A549 cells resulted in 
similar yields of viral particles for all three viruses. Nevertheless, Ad5-3∆-A20T was 
as potent as Ad5wt in tumour xenograft models in athymic mice. When injected 
intratumourally the retargeted mutant spread within the solid tumours similar to 
Ad5wt and as previously reported for Ad∆∆ (6). Complete elimination of tumours 
was not possible with either Ad5-3∆-A20T or Ad5wt because of limitations of the in 
vivo model. Murine tissues do not support productive infection with human 
adenovirus, preventing spread within the murine tumour microenvironment in 
addition to the rapid xenograft growth and the absence of an immune response (49). 
Despite the rapid hepatic elimination of adenovirus in mice, we confirmed that 
intravenous delivery of Ad5-3∆-A20T resulted in high levels of viral gene expression 
in Suit-2 tumours. Future studies will address whether the retargeted mutant will 
reach tumours in sufficiently high levels to warrant systemic administration. 
Importantly, the Suit-2 cells employed in the xenograft studies expressed lower levels 
of vß6-integrin and higher levels of vß5 compared to Panc04.03 cells. We predict 
that tumour xenografts with similar integrin-profiles, high vß6- and lower vß3- and 
vß5-integrin expression, would reflect the higher cell killing seen in vitro.  
We optimised the previously developed 3D co-culture models of pancreatic stellate 
and cancer cell lines (27-29), for investigating viral infection and spread in this study. 
These models have more similarities with the tumour microenvironment in patients 
than traditional 2D monocultures.  In addition, the interaction with human stromal 
cells is retained without interference from murine stroma present in athymic mice 
models. Although, more sophisticated organoid culture models have been described 
for murine and patient tumour tissue including a few methods for modeling pancreatic 
cancer (37, 39), we found that our 3D co-cultures were more suitable for screening of 
viral functions. We found that both Ad5-3∆-A20T and Ad5A20 were more 
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efficacious than Ad5wt and Ad∆∆ in infecting and eliminating Panc04.03 and Suit-2 
cells while in the murine models the novel retargeted Ad5-3∆-A20T had similar 
efficacy to Adwt. The collagen-matrigel matrices are likely to provide a more 
penetrable milieu for viral infectivity and spread than in dense murine stroma further 
facilitating the enhanced infectivity of Ad5-3∆-A20T as demonstrated in the 2D 
cultures. We showed that human stellate cells (PS1) support viral infection and 
replication, albeit at significantly lower levels than pancreatic cancer cells, which 
could further augment viral spread within the cultures, in contrast to the murine test 
model. Our data demonstrate that viral efficacy was retained in the 3D-cultures when 
Ad5-3∆-A20T was combined with low doses of gemcitabine. The deletion of the 
E1B19K gene causes enhancement of gemcitabine-dependent apoptosis, previously 
demonstrated for Ad∆∆ in PDAC cells (6, 11, 12, 14). We propose that the 3D co-
cultures are suitable model systems for investigating oncolytic virus replication and 
spread in the presence of the multiple cell types that constitute the tumour 
microenvironment in patients. The flexibility of the system is achieved by varying the 
cell and matrix compositions; and treatment with viruses and/or drugs can be 
administered via different compartments to enable a tailored test system appropriate 
for the research question. In conclusion, the 3D cultures complement the limitations 
of 2D cell cultures and murine in vivo models by providing a suitable platform for 
selecting the best viral mutant candidates to pursue clinically.  
Herein, we provide evidence that the complex alterations of the viral genome in the 
novel selective Ad5-3∆-A20T mutant did not compromise viral functions in vß6-
integrin expressing PDAC cells but rather enhanced infectivity and cell killing 
selectively, in these cells. In addition to the E1ACR2 and E1B19K deletions for 
replication-selectivity and apoptosis-enhancement in Ad∆∆, the E3gp19K gene was 
deleted to increase recruitment of immune cells to infected tumour cells with the aim 
to enhance efficacy in future clinical applications. We consider Ad5-3∆-A20T an 
excellent candidate for targeting pancreatic cancer. Further bio-distribution studies 
will elucidate whether additional modifications are necessary to eliminate tumours 
after systemic delivery, for example, by introducing modifications to avoid 
neutralizing antibodies and/or hepatic elimination. Our results may open new avenues 
for improving the delivery and efficacy of potent oncolytic adenoviral mutants in 
patients with pancreatic cancer. 
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Figure legends 
 
Figure 1. Higher levels of αvβ6-integrin expression in pancreatic cancer cell lines 
support higher levels of infection with the retargeted A20FMDV2-expressing 
Ad5A20 and Ad5A20-477dlTAYT mutants.  A) Fifteen pancreatic epithelial cancer 
cell lines were screened for expression of v6-integrin and CAR. Cells were probed 
with αvβ6- or CAR-specific antibodies, detected by flow cytometry and expression 
presented as Geometric Mean values, one representative study. B) Viral infectivity 
levels in the panel of cells were determined by flow cytometry. Cells were infected 
with Ad5wt, Ad5A20 and Ad5A20-477dlTAYT at 100ppc, assay was performed 48h 
post-infection and EGFP expression was quantified, one representative study. C) 
Correlation of data from studies performed as in A-B, for αvβ6-integrin expression 
and degree of infectivity of Ad5A20 (upper panel) and Ad5A20-477dlTAYT (lower 
panel). Viral infectivity is expressed as a ratio of that corresponding to Ad5wt, to 
isolate the effect on infectivity mediated by the αvβ6-integrin only. R2 values are 
displayed following linear regression analysis, one representative study out of three. 
 
Figure 2.  The cell killing potency of Ad5A20 and Ad5A20-477dlTAYT is 
significantly higher than that of Ad5wt in αvβ6-integrin expressing pancreatic 
cancer cell lines. Five pancreatic cell lines spanning low to high expression levels of 
αvβ6-integrin were selected for further studies. A) Cells were infected with Ad5wt, 
Ad5A20 and Ad5A20-477dlTAYT at 100ppc and infectivity quantified by flow 
cytometry via EGFP detection, 48h post-infection, n≥3. B) A strong correlation 
between αvβ6-integrin expression and Ad5A20/Ad5wt was observed in the five cell 
lines (R
2
=0.99). C) For each cell line viral dose-response curves were generated and 
cell viability was analysed (MTS-assay) 72h post-infection. EC50-values were 
determined for each virus and normalised to the EC50-value of Ad5wt per cell line. 
The increasing αvβ6-integrin expression levels are indicated on the graph. A and C, 
error bars represent SD, n≥3, *p<0.05, **p<0.01, One-way Anova. D) Viral DNA 
replication was quantified by qPCR. Cells were infected (100ppc) with the indicated 
viral mutant and harvested 24, 48 and 72h later. Results were compared amongst the 
three viruses by normalising the values to that of Ad5wt at 24 h and are expressed as 
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fold-change, n≥2, *p<0.01, One-way Anova comparing mutant/Adwt at indicated 
time points and 72h/24h.   
 
Figure 3. Cellular uptake of Ad5A20 and Ad5A20-477dlTAYT is blocked by free 
A20FMDV2-peptide in cells expressing high levels of αvβ6-integrin. A) 
Expression profile of the integrin receptors (αvβ3, αvβ5 and αvβ6) was determined in 
four selected pancreatic cancer cell lines. Relative expression levels were quantified 
by flow cytometry and represented by the Geo Mean values, n=3. *p<0.001 (αvβ6), 
°p<0.001 (αvβ5), compared to levels in PT45. B) To verify αvβ6-integrin mediated 
viral infection, the receptor was blocked with the αvβ6-specific peptide (FMDVp; 
10nM) prior to viral infection (100ppc), and analysed for EGFP expression 48 h later. 
n=3, *p<0.02, **p<0.01, t-test, two-tailed.  
 
Figure 4. Efficient cell killing upon delivery of Ad5wt and Ad5A20, in 3-
dimensional organotypic cultures consisting of pancreatic cancer and stromal 
cells (PS1). A) Panc04.03 or Suit-2 cells were seeded on top of a gel matrix 
consisting of collagen and Matrigel either alone (i) or co-cultured (ii) with PS1 cells. 
The co-cultured cells were infected at 1000 and 2000ppc 4d after seeding and fixed in 
formalin 4d after infection, embedded in paraffin, sectioned and stained with H/E, 5x 
magnification. For confocal imaging, cellular nuclei were detected with DAPI (blue) 
and antibodies for E1A (green). B) Ad5A20 infects both Panc04.03 and PS1 cells. 
Sections were stained with H/E (upper panels) and for confocal imaging (lower 
panels). PS1 cells were identified by -SMA expression (red) and the localisation of 
virus identified by E1A expression (green). Nuclei were detected with DAPI (blue) 
20x magnification. Area demarcated in the yellow square is magnified in the right 
panel. Infected PS1 cells appear yellow (white arrows). One representative study is 
shown, n≥3. C) Infection of PS1 cells with Adwt, Ad5A20 and Ad5A20-477dlTAYT 
(1000ppc) was challenged by blocking with αvβ5-integrin specific antibody (clone 
P1F6, 10µg/ml).  EGFP positive cells were detected by flow cytometry 72h post 
infection. D) Relative expression levels of cell surface integrins αvβ3, αvβ5, αvβ6, 
and CAR in PS1 cells, quantified by flow cytometry, n=3. E) PS1 cells were infected 
with Adwt or AdA20 (4000ppc) for 72h, virus-containing cell-free media was 
prepared, and 50µl was transferred to epithelial 2D monocultures. Panc04.03 cells 
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were trypsinised 24h later and analysed for EGFP expression by FACS, n=3. F) PS1 
cells were seeded on top of the gel, 24h later cells were infected with AdA20 
(2000ppc; right panels) or mock-treated (left panels). After 48h the cultures were 
washed to remove non-internalised virus and Panc04.03 (lower panels) or Suit2 
(upper panels) cells were seeded on top of gels, 4d later the cultures were fixed and 
stained for E1A expression (brown) and H/E, 20x magnification. Black arrows 
indicate non-infected (left panels) and infected (right panels) fibroblasts, white arrows 
indicate non-infected (left panels) and infected (right panels) epithelial cells, white 
dashed arrows point towards lysed or necrotic cells.  
 
Figure 5. The novel retargeted oncolytic mutant Ad5-3∆-A20T potently infects, 
replicates and kills co-cultured pancreatic cancer and stromal cells with and 
without gemcitabine. A) Schematic diagram of the modified Ad5-3∆-A20T derived 
from the potent and replication-selective oncolytic mutant Ad∆∆, for details see text. 
B) Viral dose-response curves were generated (MTS-assay) to compare cell viability 
of Ad∆∆ against Ad5-3∆-A20T in Panc04.03 and Suit-2 cells (left panel), and PS1 
cells (right panel), 72h post infection.  Representative study, n=3. C) Viral replication 
determined by TCID50 assay. Cells were infected with Ad5-3∆-A20T or Ad∆∆ 
(100ppc) for 48 and 72h and virus collected from media and cells and applied on 
JH293 cells for replication assay, n=2.  D) Panc04.03 cells co-cultured with PS1 cells 
in 3D collagen/matrigels. After 4 days, Ad5-3∆-A20T was applied (top panel;500-
1000ppc) or Ad∆∆ (lower panel; 500-1000ppc) in serum free media from the top of 
the cultures, harvested 4 days after infection and stained with H/E, 5x magnification. 
E) Suit-2 cells co-cultured with PS1 cells as above and 4 days after seeding infected 
with Ad-3∆-A20T at the indicated doses ± gemcitabine at 5nM, representative 
images, n=3. Cultures were harvested 4 days after infection and stained with H/E. 
Lower panels; confocal images of the corresponding sections stained for DAPI (blue; 
nuclei) and E1A (green).  
 
Figure 6. Ad5-3∆-A20T inhibits growth of Suit-2 tumour xenografts in athymic 
mice. A) Suit-2 cells (1x10
6 
cells) were inoculated subcutaneously in one flank of 
CDnu/nu athymic mice. Adenoviral mutants or PBS (mock controls) were 
administrated intra-tumourally (3x10
9
vp/injection) on day 1, 3 and 6 (arrows), when 
tumours had reached 100±20µl (14 days after inoculation). Tumor growth was 
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determined until tumors reached 1.44cm
2
. One-way Anova, ***p<0.001 compared to 
mock, 8 animals/group.  B) Kaplan Meyer survival curves generated from time to 
tumour progression set at 500µl. **p<0.01 compared to mock, n=8. C) Tissue 
sections from tumours harvested at the end of the study, stained for E1A expression 
by IHC, representative tumour images (5x and 20x magnification as shown). D) 
Detection of E1A viral protein in Suit-2 tumour lysates from animals administered a 
single tail vein injection (3x10
9
vp/100µl) with the respective virus. Animals were 
treated when tumour volumes reached  120 ± 30mm
3
 in size. Tumours were excised 
and sonicated 72h later for immunoblotting analysis, one representative study from 
two animals, 20µg total protein/lane.   
 
 
 
 






